The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 14, 2023
Filed:
Jun. 02, 2022
Applicant:
Her Majesty the Queen IN Right of Canada As Represented BY the Minister of Health, Winnipeg, CA;
Inventor:
Ma Luo, Winnipeg, CA;
Assignee:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/21 (2006.01); C07K 14/16 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01); C07K 14/74 (2006.01); A61P 37/04 (2006.01); A61P 31/18 (2006.01); A61K 9/14 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 39/12 (2013.01); C07K 14/005 (2013.01); C07K 14/161 (2013.01); C07K 14/163 (2013.01); A61K 9/14 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/57 (2013.01); A61P 31/18 (2018.01); A61P 37/04 (2018.01); C07K 14/70539 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16222 (2013.01); C12N 2740/16234 (2013.01); C12N 2740/16322 (2013.01); C12N 2740/16334 (2013.01); C12N 2760/18043 (2013.01);
Abstract
Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.